IGNE — Stock Film
STOCK FILMSCENE 1/10IGNE · $0.0000
Stock Expert AI presents
IGNE
Igene Biotechnology, Inc
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Igene Biotechnology, Inc. A quick introduction.

On the stock market since 1995, it operates in the world of raw materials. It has 18 employees. Now — the numbers.

on the stock market since 1995
18 employees
$16K market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 71% a year over the last 4 years. Red columns mark years that ended in a loss.

$463K
2003
$0
2006
$2.3M
2007
$7.6M
2008
$4M
2009
In the vault right now:
$0
DEBT: $6.8M
At this pace, that money lasts about 9.2 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
WEAK SPOTS
Growth has stalled2/10
Heavy bets against the stock2/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
The product is selling

Sales run at $4.0M a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/2
Small scale, thin loss

A loss of $141K against $4.0M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
Trading under $1

The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, IGNE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: IGNE is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film